pipeline

R&D

Brighter times ahead for biotech in 2024?

The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.

R&D

Big pharma places big bets on antibody-drug conjugates

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.

News

Moderna looks to its post-COVID growth prospects

With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influ

News

Roche removes tenecteplase from phase 3 for stroke

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects.

News

Growth is good, but GSK really needs to build its pipeline

GSK continued a run of several consecutive quarters of solid growth in the fourth quarter of 2022, helped by shingles vaccine Shingrix, but it needs to build up its pipeli

News